

Subject index

Volume 63 (2004)

Activity-retaining fragment; *Polygonatum cyrtonema* Hua; Polysaccharide; Antiviral activity; Herpes simplex virus; Structure **63**, 183

Adefovir dipivoxil; Woodchuck hepatitis virus; Drug-resistance; Antiviral therapy; Lamivudine **63**, 115

Animal model; Flavivirus; Mouse; Hamster **63**, 67

Anti-HIV activity; 1,3-Thiazolidin-4-ones; NNRTIs **63**, 79

Antiretroviral therapy; Hepatitis B; Hepatitis C; Human immunodeficiency virus; Viral load **63**, 123

Antiviral activity; *Polygonatum cyrtonema* Hua; Polysaccharide; Herpes simplex virus; Activity-retaining fragment; Structure **63**, 183

Antiviral activity; CMV; Lactoferrin; Cationized proteins; Entry inhibitors; Rat CMV model; In vivo **63**, 197

Antiviral therapy; HIV; SCID model; Hollow fiber **63**, 1

Antiviral therapy; Woodchuck hepatitis virus; Drug-resistance; Adefovir dipivoxil; Lamivudine **63**, 115

Antiviral; hMPV; Human metapneumovirus; RSV; NMSO3; Heparin **63**, 51

Antiviral; Orthopoxvirus; Cutaneous; Mice; Cidofovir **63**, 33

Antiviral; West Nile virus; Model; Hamster; Mouse; Interferon; Interferon **63**, 41

Apoptosis; Hepatitis A virus; RNA degradation; Caspase **63**, 153

Arsenite; Bovine herpesvirus-4; Endothelial cells; HSP70 **63**, 167

Bleomycin; HIV; Iron; Reactive oxygen species; Hypoxia **63**, 97

Bovine herpesvirus-4; Endothelial cells; Arsenite; HSP70 **63**, 167

Caspase; Hepatitis A virus; Apoptosis; RNA degradation **63**, 153

Cationized proteins; CMV; Lactoferrin; Antiviral activity; Entry inhibitors; Rat CMV model; In vivo **63**, 197

Cell-to-cell spread; Herpes simplex virus; PI-88; Heparan sulfate **63**, 15

Challenge; RSV; Human; Virus shedding; Microneutralizing antibody **63**, 191

Chronic hepatitis C; Dose; HCV; Interferon; Predictor; Tailored **63**, 25

Cidofovir; Ganciclovir; Human cytomegalovirus; SCID-hu mice **63**, 61

Cidofovir; Human papillomavirus; Papillomatosis; HPV; Laryngeal papillomatosis; Respiratory papillomatosis; Interferon; Indole-3-carbinol; Therapeutic vaccine **63**, 141

Cidofovir; Orthopoxvirus; Cutaneous; Mice; Antiviral **63**, 33

CMV; Lactoferrin; Cationized proteins; Antiviral activity; Entry inhibitors; Rat CMV model; In vivo **63**, 197

Cutaneous; Orthopoxvirus; Mice; Cidofovir; Antiviral **63**, 33

Cytomegalovirus; Resveratrol; Epidermal growth factor receptor **63**, 85

Dioxolane; HIV; 3TC-resistance; Nucleoside; Molecular modeling **63**, 7

Dose; Chronic hepatitis C; HCV; Interferon; Predictor; Tailored **63**, 25

Drug-resistance; Woodchuck hepatitis virus; Antiviral therapy; Adefovir dipivoxil; Lamivudine **63**, 115

Ebola virus; Lassa virus; SARS coronavirus; Real-time PCR; Imidazole nucleoside analogues **63**, 209

Endothelial cells; Bovine herpesvirus-4; Arsenite; HSP70 **63**, 167

Entry inhibitors; CMV; Lactoferrin; Cationized proteins; Antiviral activity; Rat CMV model; In vivo **63**, 197

Epidermal growth factor receptor; Resveratrol; Cytomegalovirus **63**, 85

Flavivirus; Animal model; Mouse; Hamster **63**, 67

Ganciclovir; Cidofovir; Human cytomegalovirus; SCID-hu mice **63**, 61

Hamster; Flavivirus; Animal model; Mouse **63**, 67

Hamster; West Nile virus; Model; Antiviral; Mouse; Interferon; Interferon **63**, 41

HCV; Chronic hepatitis C; Dose; Interferon; Predictor; Tailored **63**, 25

Heparan sulfate; Herpes simplex virus; Cell-to-cell spread; PI-88 **63**, 15

Heparin; hMPV; Human metapneumovirus; RSV; Antiviral; NMSO3 **63**, 51

Hepatitis A virus; Apoptosis; RNA degradation; Caspase **63**, 153

- Hepatitis B**; Antiretroviral therapy; Hepatitis C; Human immunodeficiency virus; Viral load **63**, 123
- Hepatitis C**; Antiretroviral therapy; Hepatitis B; Human immunodeficiency virus; Viral load **63**, 123
- Herpes simplex virus**; *Polygonatum cyrtonema* Hua; Polysaccharide; Antiviral activity; Activity-retaining fragment; Structure **63**, 183
- Herpes simplex virus**; Cell-to-cell spread; PI-88; Heparan sulfate **63**, 15
- HIV inhibitors**; Metabolism; Pharmacokinetics; 5'-Hydrogenphosphonate of azidothymidine **63**, 107
- HIV**; 3TC-resistance; Dioxolane; Nucleoside; Molecular modeling **63**, 7
- HIV**; Bleomycin; Iron; Reactive oxygen species; Hypoxia **63**, 97
- HIV**; SCID model; Hollow fiber; Antiviral therapy **63**, 1
- hMPV**; Human metapneumovirus; RSV; Antiviral; NMSO3; Heparin **63**, 51
- Hollow fiber**; HIV; SCID model; Antiviral therapy **63**, 1
- HPV**; Human papillomavirus; Papillomatosis; Laryngeal papillomatosis; Respiratory papillomatosis; Interferon; Cidofovir; Indole-3-carbinol; Therapeutic vaccine **63**, 141
- HSP70**; Bovine herpesvirus-4; Endothelial cells; Arsenite **63**, 167
- Human cytomegalovirus**; Ganciclovir; Cidofovir; SCID-hu mice **63**, 61
- Human immunodeficiency virus**; Antiretroviral therapy; Hepatitis B; Hepatitis C; Viral load **63**, 123
- Human metapneumovirus**; hMPV; RSV; Antiviral; NMSO3; Heparin **63**, 51
- Human papillomavirus**; Papillomatosis; HPV; Laryngeal papillomatosis; Respiratory papillomatosis; Interferon; Cidofovir; Indole-3-carbinol; Therapeutic vaccine **63**, 141
- Human**; RSV; Challenge; Virus shedding; Microneutralizing antibody **63**, 191
- 5'-Hydrogenphosphonate of azidothymidine**; Metabolism; Pharmacokinetics; HIV inhibitors **63**, 107
- Hypoxia**; Bleomycin; HIV; Iron; Reactive oxygen species **63**, 97
- IL-12**; Tenofovir; In vitro; Macaque; PMPA **63**, 133
- Imidazole nucleoside analogues**; Lassa virus; SARS coronavirus; Ebola virus; Real-time PCR **63**, 209
- In vitro**; Tenofovir; IL-12; Macaque; PMPA **63**, 133
- In vivo**; CMV; Lactoferrin; Cationized proteins; Antiviral activity; Entry inhibitors; Rat CMV model **63**, 197
- Indole-3-carbinol**; Human papillomavirus; Papillomatosis; HPV; Laryngeal papillomatosis; Respiratory papillomatosis; Interferon; Cidofovir; Therapeutic vaccine **63**, 141
- Infergen**; West Nile virus; Model; Antiviral; Hamster; Mouse; Interferon **63**, 41
- Interferon**; Chronic hepatitis C; Dose; HCV; Predictor; Tailored **63**, 25
- Interferon**; Human papillomavirus; Papillomatosis; HPV; Laryngeal papillomatosis; Respiratory papillomatosis; Cidofovir; Indole-3-carbinol; Therapeutic vaccine **63**, 141
- Interferon**; West Nile virus; Model; Antiviral; Hamster; Mouse; Infergen **63**, 41
- Iron**; Bleomycin; HIV; Reactive oxygen species; Hypoxia **63**, 97
- Lactoferrin**; CMV; Cationized proteins; Antiviral activity; Entry inhibitors; Rat CMV model; In vivo **63**, 197
- Lamivudine**; Woodchuck hepatitis virus; Drug-resistance; Antiviral therapy; Adefovir dipivoxil **63**, 115
- Laryngeal papillomatosis**; Human papillomavirus; Papillomatosis; HPV; Respiratory papillomatosis; Interferon; Cidofovir; Indole-3-carbinol; Therapeutic vaccine **63**, 141
- Lassa virus**; SARS coronavirus; Ebola virus; Real-time PCR; Imidazole nucleoside analogues **63**, 209
- Macaque**; Tenofovir; In vitro; IL-12; PMPA **63**, 133
- Metabolism**; Pharmacokinetics; HIV inhibitors; 5'-Hydrogenphosphonate of azidothymidine **63**, 107
- Mice**; Orthopoxvirus; Cutaneous; Cidofovir; Antiviral **63**, 33
- Microneutralizing antibody**; RSV; Human; Challenge; Virus shedding **63**, 191
- Model**; West Nile virus; Antiviral; Hamster; Mouse; Interferon; Infergen **63**, 41
- Molecular modeling**; HIV; 3TC-resistance; Dioxolane; Nucleoside **63**, 7
- Mouse**; Flavivirus; Animal model; Hamster **63**, 87
- Mouse**; West Nile virus; Model; Antiviral; Hamster; Interferon; Infergen **63**, 41
- NMSO3**; hMPV; Human metapneumovirus; RSV; Antiviral; Heparin **63**, 51
- NNRTIs**; 1,3-Thiazolidin-4-ones; Anti-HIV activity **63**, 79
- Nucleoside**; HIV; 3TC-resistance; Dioxolane; Molecular modeling **63**, 7
- Orthopoxvirus**; Cutaneous; Mice; Cidofovir; Antiviral **63**, 33
- Papillomatosis**; Human papillomavirus; HPV; Laryngeal papillomatosis; Respiratory papillomatosis; Interferon; Cidofovir; Indole-3-carbinol; Therapeutic vaccine **63**, 141
- Pharmacokinetics**; Metabolism; HIV inhibitors; 5'-Hydrogenphosphonate of azidothymidine **63**, 107

- PI-88**; Herpes simplex virus; Cell-to-cell spread; Heparan sulfate **63**, 15
- PMPA**; Tenofovir; In vitro; IL-12; Macaque **63**, 133
- Polygonatum cyrtonema* Hua**; Polysaccharide; Antiviral activity; Herpes simplex virus; Activity-retaining fragment; Structure **63**, 183
- Polysaccharide**; *Polygonatum cyrtonema* Hua; Antiviral activity; Herpes simplex virus; Activity-retaining fragment; Structure **63**, 183
- Predictor**; Chronic hepatitis C; Dose; HCV; Interferon; Tailored **63**, 25
- Rat CMV model**; CMV; Lactoferrin; Cationized proteins; Antiviral activity; Entry inhibitors; In vivo **63**, 197
- Reactive oxygen species**; Bleomycin; HIV; Iron; Hypoxia **63**, 97
- Real-time PCR**; Lassa virus; SARS coronavirus; Ebola virus; Imidazole nucleoside analogues **63**, 209
- Respiratory papillomatosis**; Human papillomavirus; Papillomatosis; HPV; Laryngeal papillomatosis; Interferon; Cidofovir; Indole-3-carbinol; Therapeutic vaccine **63**, 141
- Resveratrol**; Epidermal growth factor receptor; Cytomegalovirus **63**, 85
- RNA degradation**; Hepatitis A virus; Apoptosis; Caspase **63**, 153
- RSV**; hMPV; Human metapneumovirus; Antiviral; NMSO₃; Heparin **63**, 51
- RSV**; Human; Challenge; Virus shedding; Microneutralizing antibody **63**, 191
- SARS coronavirus**; Lassa virus; Ebola virus; Real-time PCR; Imidazole nucleoside analogues **63**, 209
- SCID model**; HIV; Hollow fiber; Antiviral therapy **63**, 1
- SCID-hu mice**; Ganciclovir; Cidofovir; Human cytomegalovirus **63**, 61
- Structure**; *Polygonatum cyrtonema* Hua; Polysaccharide; Antiviral activity; Herpes simplex virus; Activity-retaining fragment **63**, 183
- Tailored**; Chronic hepatitis C; Dose; HCV; Interferon; Predictor **63**, 25
- 3TC-resistance**; HIV; Dioxolane; Nucleoside; Molecular modeling **63**, 7
- Tenofovir**; In vitro; IL-12; Macaque; PMPA **63**, 133
- Therapeutic vaccine**; Human papillomavirus; Papillomatosis; HPV; Laryngeal papillomatosis; Respiratory papillomatosis; Interferon; Cidofovir; Indole-3-carbinol **63**, 141
- 1,3-Thiazolidin-4-ones**; NNRTIs; Anti-HIV activity **63**, 79
- Viral load**; Antiretroviral therapy; Hepatitis B; Hepatitis C; Human immunodeficiency virus **63**, 123
- Virus shedding**; RSV; Human; Challenge; Microneutralizing antibody **63**, 191
- West Nile virus**; Model; Antiviral; Hamster; Mouse; Interferon; Interferon **63**, 41
- Woodchuck hepatitis virus**; Drug-resistance; Antiviral therapy; Adefovir dipivoxil; Lamivudine **63**, 115